COMPANY

Envisagenics Inc.

HQ: Long Island City, NY source · envisagenics.com ↗ · Mid-Atlantic

ENVISAGENICS INC has received NIH funding, most recently in fiscal 2026 for the project “SpliceDisco: A Machine Learning Tool for the Identification of Alternative Splicing Events Directly Regulated by Pathological Splicing Factors in Cancer”. From public records Source · Oct 12, 2026

Keywords: Cancer

Profile checked Oct 10, 2026

8NIH grants

Funding and NIH signals

NIH award NIH awarded $890K (SBIR Phase II 1R44CA310213-01, new, notice Jul 21, 2026). NIH RePORTER 1R44CA310213-01 (Jul 21, 2026)
Evidence (1 event)
- Jul 21, 2026 · NIH RePORTER 1R44CA310213-01
  Organization: ENVISAGENICS, INC.; City/State: Long Island City, NY; Project number: 1R44CA310213-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 889653; Administering IC: National Cancer Institute; Project title: SpliceDisco: A Machine Learning Tool for the Identification of Alternative Splicing Events Directly Regulated by Pathological Splicing Factors in Cancer; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Series B · amount not disclosed · announced Jun 5, 2024 Company release ↗
Source quote
- Jun 5, 2024 · Company release ↗
  “New York, NY (June 5, 2024) – Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jul 21, 2026 Grant Government grant — SBIR: $889,653 (annual award, as published), announced Jul 21, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Jun 5, 2024 Raise Series B · amount not disclosed source ↗

Funding

Last 2 years.

Jul 21, 2026 Government grant — SBIR: $889,653 (annual award, as published), announced Jul 21, 2026. Agency: NIH/NCI. Source: government award database. source ↗

NIH awards 8

Annual award amounts. Total $4.2M.

Jul 12, 2023 NIH award 3R44CA265446-02S1 FY2023: $77,000 awarded for that fiscal year; activity R44 (SBIR); PI AKERMAN, MARTIN; recipient as written: ENVISAGENICS, INC., Long Island City, NY. Comprehensive validation and commerci source ↗
May 18, 2023 NIH award 5R44CA265446-02 FY2023: $980,257 awarded for that fiscal year; activity R44 (SBIR); PI AKERMAN, MARTIN; recipient as written: ENVISAGENICS, INC., Long Island City, NY. Comprehensive validation and commercia source ↗
Jun 16, 2022 NIH award 1R44CA265446-01A1 FY2022: $1,018,170 awarded for that fiscal year; activity R44 (SBIR); PI AKERMAN, MARTIN; recipient as written: ENVISAGENICS, INC., Long Island City, NY. Comprehensive validation and comme source ↗
Sep 12, 2019 NIH award 1R43CA246950-01 FY2019: $301,502 awarded for that fiscal year; activity R43 (SBIR); PI AKERMAN, MARTIN; recipient as written: ENVISAGENICS, INC., Long Island City, NY. A Software Platform for the Identifica source ↗
Mar 22, 2019 NIH award 5R44GM116478-03 FY2019: $517,226 awarded for that fiscal year; activity R44 (SBIR); PI AKERMAN, MARTIN; recipient as written: ENVISAGENICS, INC., Long Island City, NY. SpliceCore: A Cloud-Based Software Pla source ↗
Aug 31, 2018 NIH award 3R44GM116478-02A1S1 FY2018: $125,000 awarded for that fiscal year; activity R44 (SBIR); PI AKERMAN, MARTIN; recipient as written: ENVISAGENICS, INC., Long Island City, NY. SpliceCore: A Cloud-Based Software source ↗
Apr 2, 2018 NIH award 2R44GM116478-02A1 FY2018: $982,774 awarded for that fiscal year; activity R44 (SBIR); PI AKERMAN, MARTIN; recipient as written: ENVISAGENICS, INC., Long Island City, NY. SpliceCore: A Cloud-Based Software P source ↗
Aug 6, 2015 NIH award 1R43GM116478-01 FY2015: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI AKERMAN, MARTIN; recipient as written: ENVISAGENICS, INC., Long Island City, NY. SpliceCore: A cloud-based platform to source ↗